Daily Cosmetic Research Analysis
A multicenter randomized trial found no significant difference in 30-day surgical-site infections between aqueous olanexidine and chlorhexidine–alcohol for clean-contaminated surgery, reinforcing current antisepsis practice. A systematic review shows that psychosocial benefits after cosmetic surgery are uncertain and largely short-term, highlighting major evidence gaps. A pooled phase 3 analysis confirms consistent repigmentation efficacy and tolerability of topical ruxolitinib across diverse vi
Summary
A multicenter randomized trial found no significant difference in 30-day surgical-site infections between aqueous olanexidine and chlorhexidine–alcohol for clean-contaminated surgery, reinforcing current antisepsis practice. A systematic review shows that psychosocial benefits after cosmetic surgery are uncertain and largely short-term, highlighting major evidence gaps. A pooled phase 3 analysis confirms consistent repigmentation efficacy and tolerability of topical ruxolitinib across diverse vitiligo subgroups over one year.
Research Themes
- Evidence quality and outcomes in cosmetic surgery
- Dermatologic therapeutics for pigmentary disorders
- Perioperative antisepsis and infection prevention relevant to aesthetic surgery
Selected Articles
1. Efficacy of aqueous olanexidine compared with alcohol-based chlorhexidine for surgical skin antisepsis regarding the incidence of surgical-site infections in clean-contaminated surgery: a randomized superiority trial.
In five-center randomized clean-contaminated surgeries (n=700), aqueous olanexidine did not reduce 30-day SSIs versus chlorhexidine–alcohol (12.4% vs 13.6%; aRR 0.911; P=0.626). Adverse events were rare and comparable; no differences were seen across SSI subtypes or reoperation.
Impact: High-quality negative RCT clarifies that aqueous olanexidine offers no superiority over chlorhexidine–alcohol, informing antisepsis selection and stewardship.
Clinical Implications: For clean-contaminated procedures, chlorhexidine–alcohol remains a sound standard; adopting aqueous olanexidine solely to reduce SSIs is not supported. Extrapolation to clean aesthetic procedures should be cautious but suggests no clear benefit for switching.
Key Findings
- 30-day SSI incidence: 12.4% (olanexidine) vs 13.6% (chlorhexidine–alcohol); aRR 0.911; P=0.626
- No significant differences in superficial, deep, or organ/space SSIs, or reoperation due to SSI
- Adverse effects were rare and similar between groups (0.58% vs 0.87%)
Methodological Strengths
- Multicenter randomized superiority design with prespecified primary endpoint
- Trial registration and adequate sample size (n=700)
Limitations
- Conducted in clean-contaminated GI/HBP surgeries; generalizability to clean aesthetic surgery is uncertain
- Potential lack of blinding inherent to antiseptic comparisons
Future Directions: Head-to-head trials in clean surgeries, cost-effectiveness analyses, and microbiome/skin tolerability endpoints could refine antiseptic recommendations.
2. The psychosocial outcomes following cosmetic surgery are largely unknown: A systematic review.
Seventeen prospective controlled studies suggest short-term improvements in area-specific satisfaction, self-esteem, and sexual/physical well-being after cosmetic surgery, but evidence for mental health, holistic body image, QoL, and social functioning is limited and inconclusive. Overall methodological quality is poor, and long-term outcomes beyond 6 months are largely unstudied.
Impact: Challenges prevailing assumptions about psychosocial benefits of cosmetic surgery and sets a research agenda with concrete methodological recommendations.
Clinical Implications: Clinicians should avoid overpromising psychosocial benefits and incorporate validated measures with longer follow-up in practice and research. Shared decision-making should include discussion of uncertain long-term mental health and QoL outcomes.
Key Findings
- 17 prospective controlled studies were included after systematic screening and double risk assessment
- Short-term improvements in area-specific satisfaction, self-esteem, and sexual/physical well-being were suggested
- Evidence for mental health, holistic body image, QoL, and social functioning was limited and inconclusive; few studies extended beyond 6 months
- Overall methodological quality of included studies was poor with substantial heterogeneity
Methodological Strengths
- Stringent inclusion of prospective controlled studies with validated psychosocial measures
- Dual independent screening and double risk-of-bias assessment (EPHPP tool)
Limitations
- High heterogeneity across designs, controls, outcomes, and analyses limits pooling and inference
- Overall poor study quality and scarce long-term (beyond 6 months) data
Future Directions: Pre-registered, adequately powered, controlled studies with standardized, validated psychosocial outcomes and ≥12-month follow-up are needed to inform counseling and policy.
3. Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies.
Pooled phase 3 post hoc analysis (n=674) showed that 50.3% of continuous ruxolitinib users achieved F-VASI75 at Week 52 versus 28.2% after crossover, with consistent efficacy across age, sex, Fitzpatrick type, disease duration/stability, and prior treatment. Safety and treatment-related AE rates were similar across subgroups.
Impact: Supports broad applicability of topical JAK1/2 inhibition for vitiligo repigmentation across diverse patient profiles, informing equitable access and counseling.
Clinical Implications: Topical ruxolitinib can be considered across adolescent and adult patients regardless of demographics or baseline disease features; clinicians should set expectations for a year-long course and monitor for generally mild AEs.
Key Findings
- At Week 52, F-VASI75 was achieved by 50.3% with continuous ruxolitinib vs 28.2% after crossover from vehicle
- Efficacy observed across subgroups by age, sex, Fitzpatrick skin type, disease duration/stability, and prior treatment
- TEAEs in 52.1% and treatment-related AEs in 13.7%, with similar rates across demographics
Methodological Strengths
- Large pooled dataset from two phase 3 randomized trials with standardized outcome (F-VASI)
- One-year follow-up enables assessment of sustained repigmentation
Limitations
- Post hoc, descriptive subgroup analyses without multiplicity control
- Crossover design after Week 24 complicates comparative inference at Week 52
Future Directions: Prospective stratified trials and real-world studies should confirm subgroup effects, durability beyond 1 year, and optimize combination regimens (e.g., phototherapy).